Market News & Trends
Amgen Invests $200 Million in Monoclonal Antibodies
Amgen Invests $200 Million in Monoclonal Antibodies Amgen recently announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore.…
Domain Therapeutics Grants Prexton Therapeutics Exclusive License & Development Option
Domain Therapeutics S.A. recently announced that Domain Therapeutics granted Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive…
Imaxio Acquires Orphan Drug From D&A Pharma
Imaxio recently announced the acquisition of Trolovol (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. This…
MonoSol Rx Enters Licensing Agreement With Vestiq Pharmaceuticals
MonoSol Rx recently announced it has licensed Zuplenz (ondansetron) to Vestiq Pharmaceuticals, a specialty pharmaceutical company focused on innovative therapeutic remedies within the supportive…
The Quadruple Helix in the Human Genome Could Lead to New Cancer Drugs
The discovery of a quadruple helix in human cells could be a key to fighting cancer, according to the Cambridge researchers who made the…
Xceleron & Crystal Pharmatech Announce Strategic Development Partnership
Xceleron recently announced a partnership that will offer drug developers early bioavailability data that will lead to optimized solid-state forms and formulations. The partnership…
Aptuit & Aegerion Sign Long-Term API Agreement
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, recently announced that Aptuit and Aegerion Pharmaceuticals, Cambridge, MA, have signed a long-term supply agreement…
BIND Biosciences & Amgen Sign Worldwide Development & Commercialization Agreement
BIND Biosciences recently announced it has entered into a global collaboration agreement with Amgen Inc. to develop and commercialize a kinase inhibitor nanomedicine for…
Catalent Makes Major Inhalation Capabilities Investment
Catalent Pharma Solutions recently announced it will make a major investment to expand its industry-leading inhalation drug development, delivery, and supply capabilities by enhancing…
Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio
Novozymes Biopharma recently announced the introduction of a new brand and visual identity for its recombinant human albumin (rAlbumin) portfolio. As part of the…
UPM Pharmaceuticals Enhances Pre-Formulation Capabilities
UPM Pharmaceuticals recently announced it has purchased and qualified a TA Instruments Q20 Auto MDSC (Differential Scanning Calorimeter), and a TA Instruments Q50 TGA…
1/16/2013
BIND Biosciences & Amgen Sign Worldwide Development & Commercialization Agreement BIND Biosciences recently announced it has entered into a global collaboration agreement with Amgen Inc. to…
ALS Therapy Development Institute & to-BBB Collaborate on Motor Neuron Disease
The ALS Therapy Development Institute (ALS TDI) recently announced it has entered into a new collaboration with to-BBB to investigate potential treatments for ALS…
1/9/2013
Ultragenyx Secures $75 Million for Ultra-Rare Diseases Ultragenyx Pharmaceutical Inc. recently announced the successful completion of a $75-million Series B round financing led by Adage…
goBalto Secures Additional Funding for Web-Based Clinical Study Platform
 goBalto, Inc. recently announced it closed a $12 million round of venture financing, led by EDBI, the global investment arm of Singapore's Economic Development…
Halozyme Therapeutics Enters Lucrative Agreement With Pfizer
 Halozyme Therapeutics, Inc. recently announced it has entered into a worldwide collaboration and license agreement with Pfizer Inc. for the purpose of developing and…
Independent AbbVie Officially Launches
 AbbVie recently marked its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they…
Infinity Pharmaceuticals Pays Millennium $15 Million
 Infinity Pharmaceuticals, Inc. recently announced that the company amended its development and license agreement with Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Company…
Perrigo Acquires Remaining Stake in Drug Development Company for Nearly $45 Million
 Perrigo Company recently announced it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately held,…
Ultragenyx Secures $75 Million for Ultra-Rare Diseases
 Ultragenyx Pharmaceutical Inc. recently announced the successful completion of a $75-million Series B round financing led by Adage Capital Partners, LP. Joining Adage as…
